Reduction of Potentially Inappropriate Medication in the Elderly.
Journal
Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967
Informations de publication
Date de publication:
27 12 2021
27 12 2021
Historique:
received:
30
06
2021
revised:
30
06
2021
accepted:
02
11
2021
pubmed:
24
12
2021
medline:
20
4
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
Medications with an unfavorable risk-benefit profile in the elderly, and for which there are safer alternatives, are designated as potentially inappropriate medications (PIM). The RIME trial (Reduction of Potentially Inappropriate Medication in the Elderly) was based on PRISCUS, a list of PIM that was developed in 2010 for the German pharmaceuticals market. In this trial, it was studied whether special training and the PRISCUS card could lessen PIM and undesired drug-drug interactions (DDI) among elderly patients in primary care. A three-armed, cluster-randomized, controlled trial was carried out in two regions of Germany. 137 primary care practices were randomized in equal numbers to one of two intervention groups-in which either the primary care physicians alone or the entire practice team received special training-or to a control group with general instructions about medication. The primary endpoint was the percentage of patients with at least one PIM or DDI (PIM/DDI) per practice. The primary hypothesis was that at 1 year this endpoint would be more effectively lowered in the intervention groups compared to the control group. Among 1138 patients regularly taking more than five drugs, 453 (39.8%) had at least one PIM/DDI at the beginning of the trial. The percent - ages of PIM/DDI at the beginning of the trial and 1 year later were 43.0% and 41.3% in the intervention groups and 37.0% and 37.6% in the control group. The estimated intervention effect of any intervention (69 practices) versus control (68 practices) was 2.3% (p = 0.36), while that of team training (35 practices) versus physician training (34 practices) was 4.3% (p = 0.22). The interventions in the RIME trial did not significantly lower the percentage of patients with PIM or DDI.
Sections du résumé
BACKGROUND
Medications with an unfavorable risk-benefit profile in the elderly, and for which there are safer alternatives, are designated as potentially inappropriate medications (PIM). The RIME trial (Reduction of Potentially Inappropriate Medication in the Elderly) was based on PRISCUS, a list of PIM that was developed in 2010 for the German pharmaceuticals market. In this trial, it was studied whether special training and the PRISCUS card could lessen PIM and undesired drug-drug interactions (DDI) among elderly patients in primary care.
METHODS
A three-armed, cluster-randomized, controlled trial was carried out in two regions of Germany. 137 primary care practices were randomized in equal numbers to one of two intervention groups-in which either the primary care physicians alone or the entire practice team received special training-or to a control group with general instructions about medication. The primary endpoint was the percentage of patients with at least one PIM or DDI (PIM/DDI) per practice. The primary hypothesis was that at 1 year this endpoint would be more effectively lowered in the intervention groups compared to the control group.
RESULTS
Among 1138 patients regularly taking more than five drugs, 453 (39.8%) had at least one PIM/DDI at the beginning of the trial. The percent - ages of PIM/DDI at the beginning of the trial and 1 year later were 43.0% and 41.3% in the intervention groups and 37.0% and 37.6% in the control group. The estimated intervention effect of any intervention (69 practices) versus control (68 practices) was 2.3% (p = 0.36), while that of team training (35 practices) versus physician training (34 practices) was 4.3% (p = 0.22).
CONCLUSION
The interventions in the RIME trial did not significantly lower the percentage of patients with PIM or DDI.
Identifiants
pubmed: 34939917
pii: arztebl.m2021.0372
doi: 10.3238/arztebl.m2021.0372
pmc: PMC8962504
doi:
pii:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
875-882Commentaires et corrections
Type : CommentIn
Références
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jul;56(7):941-9
pubmed: 23712323
Arch Intern Med. 1991 Sep;151(9):1825-32
pubmed: 1888249
BMJ. 2002 Aug 17;325(7360):367
pubmed: 12183309
J Am Geriatr Soc. 2018 Feb;66(2):282-288
pubmed: 29265170
PLoS Med. 2006 Jun;3(6):e134
pubmed: 16737346
Dtsch Arztebl Int. 2016 Nov 4;113(44):741-748
pubmed: 27890050
Gesundheitswesen. 2015 Jan;77(1):46-52
pubmed: 24806594
J Clin Epidemiol. 2012 Sep;65(9):989-95
pubmed: 22742913
BMJ Open. 2018 Feb 24;8(2):e017740
pubmed: 29478012
BMC Fam Pract. 2015 Jan 22;16:4
pubmed: 25608946
PLoS One. 2016 Jun 02;11(6):e0156304
pubmed: 27253380
J Clin Epidemiol. 1994 Aug;47(8):891-6
pubmed: 7730892
BMJ. 2020 Jun 18;369:m1822
pubmed: 32554566
Cochrane Database Syst Rev. 2018 Sep 03;9:CD008165
pubmed: 30175841
Dtsch Arztebl Int. 2016 Sep 23;113(38):627-633
pubmed: 27743469
J Am Geriatr Soc. 2016 Jun;64(6):1210-22
pubmed: 27321600
Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):719-27
pubmed: 23585247
Eur J Clin Pharmacol. 2018 Dec;74(12):1633-1644
pubmed: 30159676
Expert Opin Drug Saf. 2018 Feb;17(2):125-137
pubmed: 29258401
Dtsch Arztebl Int. 2010 Aug;107(31-32):543-51
pubmed: 20827352
Drugs Aging. 2014 Feb;31(2):131-40
pubmed: 24353033
PLoS One. 2016 Feb 03;11(2):e0146811
pubmed: 26840396
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Am Med Dir Assoc. 2017 Mar 1;18(3):211-220
pubmed: 28131719
Eur J Clin Pharmacol. 2015 Dec;71(12):1415-27
pubmed: 26407687
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Am Geriatr Soc. 2001 Dec;49(12):1691-9
pubmed: 11844005
Dtsch Arztebl Int. 2012 Feb;109(5):69-75
pubmed: 22368709
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
J Am Med Dir Assoc. 2021 Oct;22(10):2121-2133.e24
pubmed: 33901428
Ann Fam Med. 2015 Nov;13(6):545-53
pubmed: 26553894
J Am Geriatr Soc. 2017 Oct;65(10):2265-2271
pubmed: 28804870
N Engl J Med. 2016 Mar 17;374(11):1053-64
pubmed: 26981935
Z Gerontol Geriatr. 2010 Dec;43(6):399-406
pubmed: 20967452
Int J Pharm Pract. 2019 Oct;27(5):408-423
pubmed: 30964225
Eur J Gen Pract. 2017 Dec;23(1):69-77
pubmed: 28271916
Ther Adv Drug Saf. 2020 May 12;12:2042098620918459
pubmed: 32435445
Ann Pharmacother. 2019 Oct;53(10):1005-1019
pubmed: 31129978